These two reports address the effects of varicella-zoster ... vaccine recipients than among placebo recipients (0.6% vs. 0.4%), for unknown reasons. The review authors recommend vaccine ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

What does the shingles rash looks like? Who’s at risk? And who needs the shingles vaccine? Get your questions answered in this WebMD slideshow. There are some common misconceptions about this ...

Nurse consultant Linda Nazarko explains the new RSV vaccination programme and how nurses can support patients to understand ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

Shingrix, a shingles vaccine in the U.S., provides seven to 10 years of protection following the initial two-dose ...

Trust, communication, and ease of access increase vaccine program success as the respiratory virus season progresses.

The data showed a non-inferior immune response when the vaccines were co-administered compared to when they were administered at separate visits. Co-administration was well tolerated. The company ...

Shingrix is approved to prevent shingles ... immune response when the vaccines were co-administered compared to when they were administered at separate visits. Co-administration was also well ...

2 Len Friedland, MD, Vice President of Scientific Affairs and Public Health, GSK, said: “We are excited to share data on the co‑administration of our RSV and shingles vaccines. Adult immunization ...